Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Paradigm Biocapital Advisors LP

Paradigm Biocapital Advisors LP boosted its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 3.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,531,896 shares of the company's stock after purchasing an additional 91,451 shares during the quarter. Tarsus Pharmaceuticals comprises 4.9% of Paradigm Biocapital Advisors LP's portfolio, making the stock its 6th largest position. Paradigm Biocapital Advisors LP owned approximately 6.62% of Tarsus Pharmaceuticals worth $140,191,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of TARS. Lord Abbett & CO. LLC boosted its stake in Tarsus Pharmaceuticals by 115.2% in the 4th quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company's stock worth $70,873,000 after purchasing an additional 685,111 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Tarsus Pharmaceuticals by 189.4% during the fourth quarter. Millennium Management LLC now owns 644,010 shares of the company's stock valued at $35,659,000 after purchasing an additional 421,495 shares during the period. Gilder Gagnon Howe & Co. LLC boosted its stake in shares of Tarsus Pharmaceuticals by 5,636.3% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 404,237 shares of the company's stock valued at $22,383,000 after purchasing an additional 397,190 shares during the period. Jennison Associates LLC boosted its stake in shares of Tarsus Pharmaceuticals by 14.8% during the fourth quarter. Jennison Associates LLC now owns 2,500,132 shares of the company's stock valued at $138,432,000 after purchasing an additional 321,552 shares during the period. Finally, Invesco Ltd. boosted its stake in shares of Tarsus Pharmaceuticals by 36.7% during the fourth quarter. Invesco Ltd. now owns 932,115 shares of the company's stock valued at $51,611,000 after purchasing an additional 250,018 shares during the period. Institutional investors own 90.01% of the company's stock.

Insiders Place Their Bets

In other news, CEO Bobak R. Azamian sold 8,534 shares of the stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total transaction of $427,638.74. Following the transaction, the chief executive officer now owns 53,635 shares in the company, valued at $2,687,649.85. This trade represents a 13.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel Bryan Wahl sold 3,341 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $154,654.89. Following the transaction, the general counsel now owns 58,057 shares in the company, valued at $2,687,458.53. This trade represents a 5.44% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,542 shares of company stock worth $1,581,173. Corporate insiders own 8.25% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on TARS. Oppenheimer lifted their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a report on Wednesday, January 22nd. Guggenheim boosted their target price on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Jefferies Financial Group boosted their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. HC Wainwright reiterated a "buy" rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group boosted their target price on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a report on Monday, May 5th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Tarsus Pharmaceuticals currently has an average rating of "Buy" and an average price target of $66.33.

Tarsus Pharmaceuticals Stock Up 1.4%

Shares of TARS traded up $0.63 during mid-day trading on Monday, hitting $44.33. 155,256 shares of the company traded hands, compared to its average volume of 698,166. The business has a 50 day moving average of $48.05 and a 200 day moving average of $49.23. The company has a market capitalization of $1.86 billion, a PE ratio of -11.69 and a beta of 0.94. Tarsus Pharmaceuticals, Inc. has a 1-year low of $20.08 and a 1-year high of $57.28. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The firm had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million. Equities research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.